Royalty Pharma (RPRX) FCF Margin (2019 - 2026)

Royalty Pharma has disclosed FCF Margin across 8 years of filings, most recently posting 42.16% for Q1 2026.

• FCF Margin for Q1 2026 came in at 42.16%, down 6255.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 18.97% (up 661.0% YoY), and the FY2025 annual result was 33.31%, up 2168.0% from the prior year.
• FCF Margin came in at 42.16% for Q1 2026 at Royalty Pharma, up from 15.03% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 104.71% in Q1 2025 to a low of 135.58% in Q3 2022.
• The 5-year median for FCF Margin is 42.16% (2026), against an average of 26.58%.
• Across the five-year window, FCF Margin surged 15840 bps in 2023 and slumped 11481 bps in 2024, its largest moves.
• Royalty Pharma's FCF Margin stood at 56.51% in 2022, then plunged by 168 bps to 38.52% in 2023, then surged by 208 bps to 41.46% in 2024, then plunged by 64 bps to 15.03% in 2025, then soared by 181 bps to 42.16% in 2026.
• The last three FCF Margin figures came in at 42.16% (Q1 2026), 15.03% (Q4 2025), and 42.55% (Q3 2025), per Business Quant data.